ClinicalTrials.gov
ClinicalTrials.gov Menu

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (RIFLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03098823
Recruitment Status : Active, not recruiting
First Posted : April 4, 2017
Last Update Posted : December 3, 2018
Sponsor:
Information provided by (Responsible Party):
Ampel BioSolutions, LLC

Brief Summary:
To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

Condition or disease Intervention/treatment Phase
Lupus Erythematosus, Systemic Lupus Erythematosus Fatigue Drug: RAYOS Drug: Prednisone Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus
Actual Study Start Date : September 12, 2017
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue Steroids
Drug Information available for: Prednisone

Arm Intervention/treatment
Experimental: RAYOS® Drug: RAYOS
FDA approved RAYOS for indication of fatigue in Lupus.

Active Comparator: IR prednisone Drug: Prednisone
FDA approved corticosteroid frequently used for SLE.




Primary Outcome Measures :
  1. Fatigue [ Time Frame: 3 months ]
    Fatigue as measured in FACIT-F by patient



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide written informed consent agreeing to all study procedures, before any study-specific procedures are done.
  2. Males or non-pregnant females, aged 18 years or older
  3. Diagnosis of SLE by either the American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria
  4. Fatigue measured by FACIT-F ≤30.
  5. On a stable regimen of IR prednisone (5 to 15 mg/day) for a period of at least 30 days prior to Screening, expected to remain stable for the next 6 months.
  6. On a stable SLE treatment regimen for a period of at least 30 days prior to Screening, and expected to remain stable for the next 6 months. Any of the following medications are permitted if stable for at least 30 days prior to Screening and expected to remain stable for the next 6 months:

    • Hydroxychloroquine or equivalent anti-malarial
    • Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate sodium or mycophenylate mofetil at no more than 2 grams/day), belimumab, cyclophosphamide, calcineurin inhibitors (e.g. tacrolimus, cyclosporine)
  7. Entry of daily ePRO data on 11 of 14 days during the baseline period, and completion of at least 6 out of the 8 weekly ePRO questionnaires during the baseline period
  8. Willing and able to perform and comply with all study procedures, including taking pills daily as prescribed, completing the ePROs on the smart phone, wearing the smart watch day and night, bringing the smartphone on all activities away from home (e.g., walks, errands, visiting, shopping, traveling), keeping the smartphone and smartwatch charged daily, carefully using the smartphone and smartwatch as clinical tools and keeping them secure from others, and attending monthly clinic visits as scheduled
  9. Females of childbearing potential must be currently using a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device, or use of a spermicide combined with a barrier method (e.g., condom, diaphragm) for 30 days before and 90 days after receiving the study drug

Exclusion Criteria:

  1. Previously taken any of the following medications:

    • RAYOS®
    • Rituximab within 6 months prior to Screening
    • Any investigational therapy within 3 months or 5 half-lives of the agent prior to Screening
  2. History of noncompliance with taking pills as prescribed.
  3. Rapidly progressive neurologic disease
  4. Rapidly progressive renal disease (defined by proteinuria >6 g/24 hours or equivalent using spot urine protein to creatinine ratio, or serum creatinine >2.5 mg/dL)
  5. Diagnosis of fibromyalgia
  6. Any of the following clinical laboratory abnormalities:

    • Hemoglobin <8.0 mg/dL
    • Platelet count <50,000/mm3
    • White blood count (WBC) ≤ 2000/mm3; may be 1999-1000/mm3 if stable and related to SLE
    • Absolute neutrophil count (ANC) ≤1000/mm3; may be 500-999/mm3 if stable and related to SLE
    • Aspartate transaminase (AST) or alanine transaminase (ALT) ≥3× upper limit of normal (ULN) unless related to SLE
    • Calculated creatinine clearance ≤25 mL/min per 1.73 m2 (by Cockcroft-Gault equation)
  7. Grade 3 or greater laboratory abnormality based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; Appendix 3) except for the following that are allowed:

    • Activated partial thromboplastin time (PTT) > >2.5× ULN due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy
    • Hypoalbuminemia <2 g/dL due to chronic lupus nephritis, and not related to liver disease
    • Gamma glutamyl transferase (GGT) <20× ULN due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If present, any abnormalities in the ALT and/or AST must be ≤5× ULN
  8. Pregnant or nursing, or females not using effective contraception
  9. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 1 year prior to Screening
  10. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not caused by SLE (e.g., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the Investigator, could confound the results of the study or put the subject at undue risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03098823


Locations
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
The Regents of the University of California, Los Angeles
Los Angeles, California, United States, 90095
University of California-Irvine
Orange, California, United States, 92868
Stanford University
Palo Alto, California, United States, 94304
The Regents of the University of California, San Diego
San Diego, California, United States, 92037
University of California-San Francisco
San Francisco, California, United States, 94143
United States, Connecticut
Yale School of Medicine
New Haven, Connecticut, United States, 06519
United States, Florida
University of Florida College of Medicine
Gainesville, Florida, United States, 32610
Miller School of Medicine at the University of Miami
Miami, Florida, United States, 33136
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
UMASS Memorial Medical Center-Memorial Campus
Worcester, Massachusetts, United States, 01605
United States, New York
The Hospital for Special Surgery
New York, New York, United States, 10021
Columbia University Medical Center
New York, New York, United States, 10032
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
The MetroHealth System
Cleveland, Ohio, United States, 44109
United States, Oklahoma
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Temple University
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
Ampel BioSolutions, LLC

Responsible Party: Ampel BioSolutions, LLC
ClinicalTrials.gov Identifier: NCT03098823     History of Changes
Other Study ID Numbers: AMP-002
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: December 3, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Fatigue
Lupus Erythematosus, Systemic
Signs and Symptoms
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents